Yuanyuan Fang1, Chenhong Zhang2, Hongcai Shi3, Wei Wei1, Jing Shang1, Ruizhi Zheng1, Lu Yu1, Pingping Wang1, Junpeng Yang1, Xinru Deng1, Yun Zhang1, Shasha Tang1, Xiaoyang Shi1, Yalei Liu1, Huihui Yang1, Qian Yuan1, Rui Zhai4, Huijuan Yuan5. 1. Department of Endocrinology of Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China. 2. State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China. 3. Department of Endocrinology of People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China. 4. Adfontes (Shanghai) Biotechnology Co., Ltd., Shanghai, China. 5. Department of Endocrinology of Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China hjyuan@zzu.edu.cn.
Abstract
OBJECTIVE: Type 1 and type 2 diabetes are associated with gut dysbiosis. However, the relationship between the gut microbiota and latent autoimmune diabetes in adults (LADA), sharing clinical and metabolic features with classic type 1 and type 2 diabetes, remains unclear. Here, we used a multiomics approach to identify the characteristics of the gut microbiota and metabolic profiles in patients with LADA. RESEARCH DESIGN AND METHODS: This age- and sex-matched case-control study included 30 patients with LADA, 31 patients with classic type 1 diabetes, 30 patients with type 2 diabetes, and 29 healthy individuals. The gut microbiota profiles were identified through the 16S rRNA gene, and fecal and serum metabolites were measured through untargeted liquid chromatography-mass spectrometry. RESULTS: Patients with LADA had a significantly different structure and composition of the gut microbiota and their metabolites as well as a severe deficiency of short-chain fatty acid-producing bacteria. The gut microbiota structure of the patients with LADA was more similar to that of patients with type 1 diabetes who were positive for GAD antibody. We identified seven serum metabolite modules and eight fecal metabolite modules that differed between the LADA group and the other groups. CONCLUSIONS: The characteristic gut microbiota and related metabolites of patients with LADA are associated with autoantibodies, glucose metabolism, islet function, and inflammatory factors, which may contribute to the pathogenesis of LADA. Future longitudinal studies should explore whether modulating the gut microbiota and related metabolites can alter the natural course of autoimmune diabetes in the quest for new therapeutics.
OBJECTIVE: Type 1 and type 2 diabetes are associated with gut dysbiosis. However, the relationship between the gut microbiota and latent autoimmune diabetes in adults (LADA), sharing clinical and metabolic features with classic type 1 and type 2 diabetes, remains unclear. Here, we used a multiomics approach to identify the characteristics of the gut microbiota and metabolic profiles in patients with LADA. RESEARCH DESIGN AND METHODS: This age- and sex-matched case-control study included 30 patients with LADA, 31 patients with classic type 1 diabetes, 30 patients with type 2 diabetes, and 29 healthy individuals. The gut microbiota profiles were identified through the 16S rRNA gene, and fecal and serum metabolites were measured through untargeted liquid chromatography-mass spectrometry. RESULTS: Patients with LADA had a significantly different structure and composition of the gut microbiota and their metabolites as well as a severe deficiency of short-chain fatty acid-producing bacteria. The gut microbiota structure of the patients with LADA was more similar to that of patients with type 1 diabetes who were positive for GAD antibody. We identified seven serum metabolite modules and eight fecal metabolite modules that differed between the LADA group and the other groups. CONCLUSIONS: The characteristic gut microbiota and related metabolites of patients with LADA are associated with autoantibodies, glucose metabolism, islet function, and inflammatory factors, which may contribute to the pathogenesis of LADA. Future longitudinal studies should explore whether modulating the gut microbiota and related metabolites can alter the natural course of autoimmune diabetes in the quest for new therapeutics.
Authors: Yan Zheng; Yanping Li; Qibin Qi; Adela Hruby; JoAnn E Manson; Walter C Willett; Brian M Wolpin; Frank B Hu; Lu Qi Journal: Int J Epidemiol Date: 2016-07-13 Impact factor: 7.196
Authors: Nicole E Cummings; Elizabeth M Williams; Ildiko Kasza; Elizabeth N Konon; Michael D Schaid; Brian A Schmidt; Chetan Poudel; Dawn S Sherman; Deyang Yu; Sebastian I Arriola Apelo; Sara E Cottrell; Gabriella Geiger; Macy E Barnes; Jaclyn A Wisinski; Rachel J Fenske; Kristina A Matkowskyj; Michelle E Kimple; Caroline M Alexander; Matthew J Merrins; Dudley W Lamming Journal: J Physiol Date: 2017-12-27 Impact factor: 5.182
Authors: Anna Klindworth; Elmar Pruesse; Timmy Schweer; Jörg Peplies; Christian Quast; Matthias Horn; Frank Oliver Glöckner Journal: Nucleic Acids Res Date: 2012-08-28 Impact factor: 16.971
Authors: Raffaella Buzzetti; Ernesto Maddaloni; Jason Gaglia; R David Leslie; F Susan Wong; Bernhard O Boehm Journal: Nat Rev Dis Primers Date: 2022-09-22 Impact factor: 65.038